安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Personalis | Transforming the Active Management of Cancer
Personalis is revolutionizing cancer care with combined expertise in advanced testing, cancer genomics, and data science Partner with us to unlock the potential of personalized treatments, drive groundbreaking innovations and better patient outcomes
- Personalis, Inc. (PSNL) - Yahoo Finance
Find the latest Personalis, Inc (PSNL) stock quote, history, news and other vital information to help you with your stock trading and investing
- Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy . . .
Personalis, Inc is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions Click for more on PSNL stock
- Personalis (PSNL) Stock Price Overview
A detailed overview of Personalis, Inc (PSNL) stock, including real-time price, chart, key statistics, news, and more
- Personalis Reports Fourth Quarter and Full Year 2025 Results . . . - BioSpace
FREMONT, Calif -- (BUSINESS WIRE)--Personalis, Inc (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025 and recent business highlights and provided financial guidance for the full year 2026
- Personalis Inc. Stock Quote (U. S. : Nasdaq) - MarketWatch
Personalis, Inc engages in the provision of advanced genomic tests for cancer The firm is also involved in providing sequencing and data analysis services to support population sequencing
- Personalis Reports First Quarter Results and Recent Highlights
Personalis, Inc (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the first quarter ended March 31, 2026, highlighted
- Personalis (PSNL) Stock Price, News Analysis - MarketBeat
Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine
|
|
|